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Abstract
Background: Chronic obstructive pulmonary disease (COPD) imparts a substantial economic burden on western
health systems. Our objective was to analyze the determinants of elevated healthcare utilization among patients
with COPD in a single-payer health system.
Methods: Three-hundred eighty-nine adults with COPD were matched 1:3 to controls by age, gender and area of
residency. Total healthcare cost 5 years prior recruitment and presence of comorbidities were obtained from a
computerized database. Health related quality of life (HRQoL) indices were obtained using validated questionnaires
among a subsample of 177 patients.
Results: Healthcare utilization was 3.4-fold higher among COPD patients compared with controls (p < 0.001). The
“most-costly” upper 25% of COPD patients (n = 98) consumed 63% of all costs. Multivariate analysis revealed that
independent determinants of being in the “most costly” group were (OR; 95% CI): age-adjusted Charlson
Comorbidity Index (1.09; 1.01 - 1.2), history of: myocardial infarct (2.87; 1.5 - 5.5), congestive heart failure (3.52;
1.9 - 6.4), mild liver disease (3.83; 1.3 - 11.2) and diabetes (2.02; 1.1 - 3.6). Bivariate analysis revealed that cost
increased as HRQoL declined and severity of airflow obstruction increased but these were not independent
determinants in a multivariate analysis.
Conclusion: Comorbidity burden determines elevated utilization for COPD patients. Decision makers should
prioritize scarce health care resources to a better care management of the “most costly” patients.
Background
Chronic obstructive pulmonary disease (COPD) is a com-
mon respiratory disease affecting more than 10% of
adults aged ≥40 yrs [1]. COPD is a leading cause of mor-
tality worldwide [2] and it imparts a substantial economic
burden on western health systems [2,3]. It is often
accompanied by exacerbations of respiratory symptoms
requiring hospitalization [4,5], and therefore is associated
with increased health care utilization [1,6,7]. Difference
in healthcare cost estimates may stem from differences in
payment schemes applied in health system [8]. These in
turn may be related to differences in availability and
practice patterns. To date, few studies have been con-
ducted in single-payer systems in which availability of
resources and practice mandates are uniform.
Concomitant comorbidities among COPD patients are
associated with elevated healthcare costs [9,10]. These
include other major system diseases such as cardiac,
liver, and endocrine disorders such as diabetes. In addi-
tion, comorbidities that could influence health costs
include sleep disorders such as obstructive sleep apnea
(OSA) and insomnia [11,12].
In the present study, we analyzed the determinants of
health care utilization, incorporating measures of sleep
quality, general and disease specific health related qual-
ity of life (HRQoL) and comorbidity burden in a single-
payer health system. We hypothesized that HRQoL,
sleep disturbances, and comorbidity burden determine
elevation of health care utilization in COPD patients.
Methods
Setting
A cross-sectional observational study was conducted at
t h eP u l m o n a r yC l i n i co ft h eS o r o k aU n i v e r s i t yM e d i c a l
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population of approximately 550,000. Ninety-five per-
cent of patients in this clinic are enrollees of the Clalit
Health Services (CHS), the largest health maintenance
organization in Israel. The study was approved by the
Institutional Ethics Committee (approval number 10283)
as well as the committee of Clalit Health Services for
extracting data from the database.
Patients
From March 2009 through December 2009, we prospec-
tively recruited patients (n = 389) attending routine
clinic appointments who met the following criteria: 1)
enrollees of CHS, 2) age >35, 3) smoking history of ≥ 10
pack-years, 4) pulmonologist-diagnosed COPD. Exclu-
sion criteria were: 1) other major pulmonary diagnoses,
2) concomitant disease expected to shorten life span to
<3 years (determined from chart review by one of the
investigators - NM), 3) exacerbations of COPD and/or
hospitalization/urgent care visits within the month prior
to recruitment (in order to obtain both clinical and
HRQoL indices from stable patients). As a part of
another study on HRQoL in COPD [13,14], in a subset
of 177 patients, data were collected on HRQoL as well
as measures of sleep quality. As control subjects,
patients without COPD were randomly selected from
the database of CHS enrollees, matched 1:3 to the
COPD patients (n = 1,167) by age, gender, primary-care
clinic and area of residency.
Measures
Spirometric indices of lung function [15] were obtained
within 6 months prior to the sentinel clinic visit from
the patient’s medical record at the pulmonary clinic, and
included forced vital capacity (FVC) and forced expired
volume in one second (FEV1). Disease severity was
staged according to the Global Initiative for Lung Dis-
ease (GOLD - 2006) [16], and % predicted FEV1. Demo-
graphics including age, gender, body mass index (BMI),
smoking status (current, ex-smoker), and pack-years
smoking, were obtained from the patient’s medical
record at the pulmonary clinic. In the subset of 177
patients, indices of Health Related Quality of Life
(HRQoL) and sleep quality were obtained using trained
interviewers as described in another study of our group
[13,14] applying Hebrew translations of four-week recall
questionnaires that included: 1) a generic questionnaire,
the Health Utilities Index 3 (HUI3); 2) a disease specific
questionnaire, the St. George’s Respiratory Question-
naire (SGRQ); and 3) the Pittsburgh Sleep Quality Index
(PSQI). Among this subset we collected data on socioe-
conomic status including: income relative to the Israeli
average income, years of schooling, employment status
and marital status. The presence of Comorbidities was
obtained from CHS database, using the International
Classification of Diseases, Ninth Revision (ICD-9) codes.
The age-adjusted Charlson Comorbidity Score with
Deyo Modification (CCI) [17] was calculated accord-
ingly. Additionally, we assessed the presence of hyper-
tension, depression, obstructive sleep apnea and
pulmonary hypertension (that are not included in CCI
and commonly found in COPD patients).
Information regarding annualized health care utiliza-
tion was obtained for the five year period prior to the
end of recruitment period (December 15, 2009) from
the CHS financial database [18]. Under the obligatory
Israeli National Health Insurance Law, all citizens have
equal access to medical services. Physicians are generally
paid a capitation fee and thus do not have economic
incentive to increase healthcare consumption. Indicators
of health care utilization included: hospitalization, emer-
gency department visits, visits to specialists (consulta-
tions), surgeries including operative procedures such as
cardiac catheterization and heart or spinal column sur-
geries, diagnostic procedures including CT scans, Ultra-
sound, MRI and spirometry, and medication according
to the WHO classification system [19]. Although
patients who had exacerbations of COPD and/or hospi-
talization/urgent care visits within the month prior to
recruitment were excluded, our retrospective analysis
over 5 years included patients who experienced exacer-
bation during these years but the data for the number
of exacerbation were not available. Utilization costs esti-
mates were based on a standardized price-list published
by the Israeli Ministry of Health in 2009. Medication
costs estimates were based on a price-list published by
the CHS. All costs are expressed in US dollars ($) with
an assumed exchange rate of 3.7 New Israeli Shekels per
US dollar.
Data and Statistical Analysis
Data were analyzed using STATA software (ver 11.0,
StataCorp, USA). Non-normally distributed variables
were presented as median with 25-75 percentiles unless
otherwise specified. Dichotomous indicator values were
presented as proportions. Since health care utilization
costs are not normally distributed, we stratified our
COPD patients cohort into two subgroups [18]- the
upper 25% (n = 98) who were the “most costly” patients
and the “remaining” 75% (n = 291). Comparison
between group medians was done using Mann-Whitney
U test, and between proportions using Chi-square test.
Regression was done using the least-squares technique.
The null hypothesis was rejected at the 5% level.
Significant bivariate predictors of elevated health care
utilization were put into a multivariate logistic regres-
sion. Independent variables included: age, gender, BMI,
disease severity (percent predicted FEV1,G O L Dc l a s s ) ,
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smoking history (pack-yrs), HUI3, SGRQ, PSQI. In
order to examine whether the model has predictive abil-
ity we obtained the area under the receiver operating
characteristic (ROC) curve.
Results
Three hundred eighty nine patients with COPD were
included in our cohort (median age of 68 and 78% male
gender). The non-COPD control subject were similar in
age and gender, but had lower comorbidity burden as
measured by age-adjusted CCI (4 vs. 7, p < 0.001). The
most prevalent diseases (>30% of the population) in this
group were hypertension, connective tissue disease and
diabetes. As depicted in Table 1, the median annualized
cost of health care for the entire COPD cohort (n =
389) was $2200 (25 - 75 percentiles: $1139 - $4934), 3.4
times higher than the non-COPD controls (p < 0.001).
This elevated healthcare consumption stemmed mainly
from increased utilization of hospitalization, medication
and diagnostic procedures.
As demonstrated in Table 2, the subset of 177 COPD
patients that were interviewed resembled the entire
COPD cohort (n = 389) with regard to demographic
characteristics, severity of airflow obstruction, smoking
history, comorbidity burden and healthcare costs. The
“most costly” COPD patients (n = 98) consumed 63% of
all costs and had a median annualized cost of $7692 per
patient (25 - 75 percentiles: $6365 - $9892), 4.7 times
higher than the remainder (n = 291), whose median
annualized cost was $1632 (25 - 75 percentiles: $949 -
$2660, p < 0.001). The characteristics of the “most
costly” patients compared to the rest of the study popu-
lation are summarized in Table 3. Compared to the rest
of the patients, the “most costly” patients were older
had significantly more comorbid conditions and higher
age adjusted CCI. The most costly patients had signifi-
cantly lower percent predicted FEV1 than the others but
were not different in severity class according to the
GOLD criteria. In addition, no significant differences
were found between groups in BMI and smoking history
(pack-yrs). In the subset of 177 COPD patients, we
found no significant difference between the “most
costly” patients and the remainders in socioeconomic
status and HRQoL indices.
The most prevalent comorbidities among the “most
costly” patients were: hypertension, myocardial infarct,
congestive heart failure and diabetes mellitus (Table 4).
These comorbidities are significantly more prevalent in
this sub-group compared to the rest of the patients.
Connective tissue disease is also a common comorbidity
among the “most costly” patients, but its prevalence is
not significantly different from that among the rest of
the patients. There was no evidence of increased odds
for the presence of either OSA or depression/anxiety
among the “most costly” group compared to the
“remainder”.
All health care utilization components were signifi-
cantly greater among the “most costly” patient com-
pared to the rest of the patients (Table 5). Predominant
components of patients’ health care utilization are hos-
pitalization, surgeries, diagnostic procedures and
Table 1 Comparison of total cost elements between
COPD patients and matched controls
control
(n = 1167)
COPD
(n = 389)
P value*
Annualized Total Cost 1634 ± 2480 3823 ± 4794 <0.001
(US$/person) 652
(225 - 2013)
2200
(1139 - 4934)
Hospitalization 410 ± 1083 1474 ± 2428 <0.001
Annualized Costs
($US/person)
0 (0 - 352) 615
(106 - 1614)
Surgeries 564 ± 1309 825 ± 1789 <0.001
Annualized Costs
($US/person)
0 (0 - 477) 0 (0 - 675)
Diagnostic procedures 222 ± 256 440 ± 349 <0.001
Annualized Costs
($US/person)
133
(40 - 316)
348
(184 - 607)
Consultations 89 ± 94 201 ± 148 <0.001
Annualized Costs
($US/person)
59 (24 - 124) 171 (88 - 271)
Emergency Room Visit 33 ± 51 56 ± 80 <0.001
Annualized Costs
($US/person)
27 (0 - 55) 29 ( 0 - 59)
Medication 297 ± 1042 790 ± 3031 <0.001
Annualized Costs
($US/person)
104
(28 - 288)
414 (220 - 725)
Values are presented as mean ± SD and median (25-75 percentiles).
* Mann-Whitney U test.
Table 2 Comparison of characteristics between entire
cohort and the subset group
Variable Entire cohort The subset
group
P
value
N 389 177
Age (yrs)* 68 (59 - 77) 67 (60 - 74) 0.25
†
Males (%) 77.6% 78.0% 0.93
‡
BMI (kg/m
2)* 27 (24 - 31) 27 (23 - 30) 0.57
†
Pack yrs smoking (yrs)* 50 (30 - 80) 40 (28 - 60) 0.07
†
FEV1 (% predicted)* 47 (37 - 60) 46 (36 - 58) 0.49
†
GOLD class 3 or 4 54.0% 59.9% 0.19
‡
Age adjusted CCI* 7 (4 - 9) 6 (4 - 9) 0.71
†
Annualized healthcare
cost*
2200 (1139 -
4934)
2312 (1139 -
5519)
0.61
†
Abbreviations: BMI- body mass index, FEV1- forced expired volume in one
second (as percent predicted), GOLD- global initiative for chronic obstructive
lung disease, CCI- Charlson Comorbidity Index.
* median (25-75 percentiles);
† Mann-Whitney U test;
‡ Chi-square test.
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among the “most costly” patients were related to heart
disease, i.e. cardiac catheterization, heart surgery and
implantation of a pace-maker.
The median annualized medication cost for the “most
costly” patient was 2.1 times higher than among the
remainder. Table 6 depicts drug utilization according to
drug classification. The most frequently used drugs were
those categorized as respiratory, cardiovascular, alimen-
tary tract and metabolism. The consumption of analge-
sics, psycholeptics and psychoanaleptics was low but
significantly higher among the “most costly” patients.
In the subset of 177 patients in whom we collected
HRQoL data, bivariate regression between HRQoL
indices (as measured by PSQI, SGRQ and HUI3) and
annualized healthcare cost revealed that cost increased as
HRQoL declined for all measures (PSQI: slope = 85.9,
p = 0.04, adjusted R-squared = 0.02; SGRQ: slope = 22.7,
p = 0.03, adjusted R-squared = 0.02; HUI3: slope =
-1656.2, p = 0.003, adjusted R-squared = 0.04). However,
these indices did not remain as independent predictors of
cost in the presence of comorbidity burden in the multi-
variate model.
Multivariate logistic regression, adjusting for age, FEV1
and BMI, revealed that comorbidity burden (as mea-
sured by age-adjusted CCI) and the presence of myocar-
dial infarct, congestive heart failure, mild liver disease
and diabetes mellitus were independent determinants
for being “most costly” COPD patients (Table 7). The
area under the ROC curve was 0.82, implying that the
model has strong predictive power.
Discussion
In this study, we have provided additional evidence of
higher healthcare cost in COPD patients compared to
matched non-COPD controls. In addition, our results
demonstrated that the odds of being among the most
costly COPD patient were associated with comorbidity
burden as well as specific comorbidities, namely: conco-
mitant heart disease (myocardial infarct, congestive
heart failure), mild liver disease and diabetes mellitus.
Severity of airflow obstruction and HRQoL indices were
not independent determinants of increased health care
utilization. The following discussion considers these
results in light of the currently available literature.
Elevated healthcare utilization
COPD patients consumed 3.4 times higher healthcare
resources compared to controls. Since control subjects
were randomly matched 1:3 to COPD cohort by age, it
can be assumed that most characteristics are typical to
this age range except for the elevated burden associated
with COPD. Similar trends have been found previously
[6,7,10]. Two studies conducted among Medicaid enrol-
lees older than 45 in Maryland [7,10] showed that that
COPD patients consumed 1.33 time greater healthcare
resources and had 1.8 times greater adjusted average
number of inpatient claims compared to controls. Mapel
et al. [6] found that healthcare utilization among COPD
patients in New Mexico was approximately twice that of
age and gender matched controls. Our results extend
these previous ones showing that the same trends apply
in a single-payer health system including various socioe-
conomic groups and extended age range. Our estimates
may differ from those observed in other countries [1]
due to variety of factors, among which the most impor-
tant are: patients’ selection method, differences in health
system’s payment schemes and in price-lists.
The effect of comorbidities
Each increase in age-adjusted CCI increased the odds of
being a “most costly” COPD patient. The specific
comorbidities predicting being in the “most costly”
group were myocardial infarction, congestive heart fail-
ure, mild liver disease and diabetes. In the study of Lin
Table 3 Characteristics of adult COPD patients (n = 389)-
Comparison between the “Most costly” patients and the
remainder
Variable “Most costly”* The remainder P value
N 98 291
Age (yrs)
† 70 (65 - 77) 67 (58 - 76) 0.003
‡
Males (%) 84.7% 75.3% 0.05
§
BMI (kg/m
2)
† 27 (24 - 30) 27 (24 - 31) 0.74
‡
Pack yrs smoking (yrs)
† 50 (35 - 80) 50 (29 - 75) 0.10
‡
FEV1 (% predicted)
† 44 (33 - 56) 49 (38 - 61) 0.03
‡
GOLD class 3 or 4 62.2% 51.2% 0.06
§
Number of morbidity
conditions
†
6 (4 - 8) 3 (1 - 4) <0.001
‡
Age adjusted CCI
† 9 (7 - 11) 5 (3 - 8) <0.001
‡
Education
(yrs of schooling)
†,‖
12 (8 - 12) 10 (4 - 12) 0.07
‡
Low 83% 80%
Income
¶,‖ Average 10% 10% 0.85
§
High 7% 10%
PSQI
†,‖ 13 (7 - 16) 11 (6 - 16) 0.48
‡
SGRQ
†,‖ 67.7 (43.5 - 77.1) 57.7 (41.8 - 72.3) 0.17
‡
HUI3
†,‖ 0.6 (0.3 - 0.7) 0.7 (0.3 - 0.8) 0.13
‡
Abbreviations: BMI- body mass index, FEV1- forced expired volume in one
second (as percent predicted), GOLD- global initiative for chronic obstructive
lung disease, CCI- Charlson Comorbidity Index, PSQI- Pittsburgh sleep quality
index, SGRQ- St Georges Respiratory Questionnaire, HUI3- health utilities index
mark 3.
* The “most costly” patients are those whose annualized utilization cost was
within the upper 25 percentile;
† median (25-75 percentiles);
‡ Mann-Whitney
U test;
§ Chi-square test;
‖ This indicator was calculated on the subsample of
177 patients;
¶ Self reported income levels were defined as Low/Average/High
relative to the average monthly income ($2,160/month).
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tion in COPD patients compared with others were dia-
betes with organ damage, peptic ulcer, congestive heart
failure and mild liver disease. Thus, a number of the
determinants of health care utilization in COPD patients
compared with non-COPD patients also determine ele-
vated health care costs within the COPD patient group.
Even though our patients are from an extended age
range with an older mean compared those of Lin et al,
in both groups heart disease, diabetes and liver disease
figure prominently as important comorbidities increas-
ing health care utilization.
The connection between cardiovascular disease and
COPD has been reported previously [6,20,21]. In our
sample, these findings were reinforced by our findings
that both congestive heart failure and myocardial infarc-
tion were independent predictors of being in the “most
costly” group. Further, our results revealed increased
utilization of cardiovascular drugs and increased costs
related to cardiac surgeries among the “most costly”
patients. Thus, it appears that managing care of COPD
with concomitant cardiovascular disease should be one
of the major foci for intervention in patients with
COPD.
T h ep r e s e n c eo fm i l dl i v e rd i s e a s ei n c r e a s e dt h eo d d s
of belonging to the “most costly” COPD patient.
Although there is no single pathogenetic mechanism
involved, chronic liver dysfunction may cause pulmon-
ary manifestations because of alterations in the produc-
tion or clearance of circulating cytokines and other
mediators [22]. Further, this association may be related
to the effect of smoking that is an important risk factor
for COPD and is commonly reported by patients with
advanced liver disease.
The co-presence of diabetes was an additional predic-
tor for increased health care utilization. This result is
consistent with previous studies showing that diabetes is
a predictor of longer hospitalizations and adverse clini-
cal outcomes in patients with acute exacerbations of
COPD [5,23]. In this regard, increased length of stay
was a component of increased health care utilization for
the “most costly” patients. From the database, we cannot
determine precisely whether the “most costly” patients’
hospitalizations were longer due to poor glucose control,
but this could have been one contributor.
COPD is associated with significantly higher risk of
having anxiety/depressive symptoms [24]. Recent studies
had demonstrated that these symptoms among COPD
Table 4 Prevalence of comorbidities among the “most costly” patients compared to the remainder
Comorbidity condition (ICD-9 codes) Prevalence
“Most costly”* (n = 98) The remainder (n = 291) P value
† OR 95% CI
Hypertension (401 - 405) 74% 54% <0.001 2.53 1.5 - 4.2
Myocardial infarct (410, 411) 70% 29% <0.001 5.96 3.6 - 9.9
Connective tissue disease (710, 714, 725) 58% 57% 0.89 1.03 0.6 - 1.6
Congestive heart failure (398, 402, 428) 52% 14% <0.001 6.81 4.1 - 11.4
Diabetes Mellitus (250) 50% 24% <0.001 3.10 1.9 - 5.0
Moderate and severe renal disease (403, 404, 580 - 586) 37% 20% 0.001 2.38 1.4 - 3.9
Hemiplegia (342, 434, 436, 437) 29% 13% <0.001 2.66 1.5 - 4.6
Peripheral vascular disease (440 - 447) 24% 13% 0.01 2.09 1.2 - 3.7
Cerebrovascular disease (430 - 433, 435) 23% 12% 0.01 2.17 1.2 - 3.9
Depression/Anxiety (296.2, 296.3, 311) 23% 15% 0.06 1.72 1.0 - 3.0
Peptic ulcer (531 - 534) 22% 15% 0.08 1.67 0.9 - 3.0
Diabetes Mellitus with organ damage (250.4 - 250.7) 21% 9% 0.001 2.78 1.5 - 5.2
Pulmonary hypertension (415, 416) 20% 7% <0.001 3.67 1.9 - 7.2
Any tumor (140 - 195) 17% 10% 0.05 1.90 1.0 - 3.6
Obstructive sleep apnea (780.51, 780.53) 16% 9% 0.06 1.89 1.0 - 3.7
Mild liver disease (571, 573) 8% 3% 0.02 3.14 1.1 - 8.6
Moderate or severe liver disease (070, 570, 572) 7% 2% 0.01 4.40 1.4 - 14.2
Dementia (290, 291, 294) 3% 2% 0.42 1.81 0.4 - 7.7
Lymphoma (200, 202, 203) 1% 0% 0.42 2.99 0.2 - 48.4
Metastatic solid tumor (196 - 199) 1% 2% 0.63 0.59 0.1 - 5.1
Leukemia (204-208) 1% 1% 0.74 1.49 0.1-16.7
None of the patients in this cohort had AIDS.
* The “most costly” patients are those whose annualized utilization cost was within the upper 25 percentile;
† Chi-square test.
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exacerbations and hospitalization [25,26]. Hence, we
expected that patients with COPD with elevated health
care utilization would have been more likely to be diag-
nosed with anxiety and/or depression and would have
thus consumed drugs to treat these conditions.
Although our study did not include measures of anxiety
a n dd e p r e s s i o n ,w ef o u n dt h a tt h e r ew a sn os i g n i f i c a n t
difference between the most costly patient and the
remainder in the prevalence of anxiety and depression,
and the utilization of psychoactive drugs was low. This
result may stem from the study population size, the will-
ingness of physicians to address anxiety/depression in
their COPD patients, or local practice patterns and
needs further examination.
We found that the presence of concurrent OSA was
not an independent predictor of elevated healthcare
utilization. These results appear to be in conflict with
the results of Shaya and colleagues [12] showing that
the presence of OSA adds additional economic burden
on beneficiaries who already have COPD. The discre-
pancy may relate to the fact that in neither study were
attempts made to assess the true prevalence of OSA in
COPD patients. However, the proportion of patients
with OSA in the “most costly” group was greater in our
study, but did not reach statistical significance. The
sample of Shaya et al was considerably larger than ours,
a n di ti sp o s s i b l et h a tw i t hl a r g e rn u m b e r s ,o u rc o n c l u -
sions would have been the same as those of Shaya et al.
The effect of airflow obstruction
Interestingly, the severity of airflow obstruction was not
an independent predictor of health care cost on multi-
variate analysis. It appears that once a patient has
Table 5 Comparison of total cost elements between the “Most costly” COPD patients and the remainder
“Most costly”*(n = 98) The remainder (n = 291) P value
†
Annualized Total Cost 9681 ± 6475 1899 ± 1185 <0.001
(US$/person) 7692 (6365 - 9892) 1632 (949 - 2660)
Hospitalization 4129 ± 3549 607 ± 745 <0.001
Annualized Costs ($US/person) 3147 (1567 - 6061) 352 (0 - 875)
Annualized Days/person 10.4 ± 10.7 1.4 ± 1.7 <0.001
7.4 (3.6 - 13.8) 0.8 (0 - 2.0)
Annualized 2.4 ± 1.9 0.5 ± 0.6 <0.001
Admissions/person 1.9 (1.0 - 3.0) 0.2 (0 - 0.6)
Average Length 4.3 ± 2.4 3.4 ± 2.2 <0.001
Days/Admission 3.7 (3.0 - 4.9) 3.0 (2.0 - 4.0)
Surgeries 2557 ± 2817 268 ± 565 <0.001
Annualized Costs ($US/person) 1991 (477 - 4166) 0 (0 - 238)
Annualized 0.4 ± 0.3 0.1 ± 0.1 <0.001
Number/person 0.4 (0.2 - 0.6) 0 (0 - 0.2)
Diagnostic procedures 676 ± 444 357 ± 264 <0.001
Annualized Costs ($US/person) 631 (339 - 849) 289 (161 - 506)
Annualized 8.6 ± 4.9 5.5 ± 3.4 <0.001
Number/person 7.4 (5.2 - 12.2) 4.8 (3.0 - 7.2)
Consultations 278 ± 180 174 ± 124 <0.001
Annualized Costs ($US/person) 256 (141 - 381) 157 (77 - 240)
Annualized 9.1 ± 6.0 5.7 ± 4.0 <0.001
Visits/person 8.2 (4.4 - 12.6) 5.0 (2.4 - 8.0)
Emergency Room Visit 108 ± 121 40 ± 51 <0.001
Annualized Costs ($US/person) 59 (29 - 147) 29 ( 0 - 59)
Annualized 0.7 ± 0.8 0.3 ± 0.3 <0.001
Visits/person 0.4 (0.2 - 1.0) 0.2 (0 - 0.4)
Medication 1856 ± 5855 432 ± 327 <0.001
Annualized Costs ($US/person) 709 (420 - 1171) 340 (191 - 636)
Annualized Number of 109.8 ± 51.3 63.8 ± 45.4 <0.001
Prescriptions/person 104.1 (72.4 - 139.2) 53.0 (30.0 - 93.6)
Values are presented as mean ± SD and median (25-75 percentiles).
* The “most costly” patients are those whose annualized utilization cost was within the upper 25 percentile.
† Mann-Whitney U test.
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health care utilization cost. Thus, the physiological
impairment, while predicting mortality [5,20], does not
predict health care utilization independently of other
comorbid conditions.
The effect of HRQoL
Our study demonstrated that as indices of health related
quality of life (HRQoL) decline, annualized healthcare
utilization increases. However, when the burden of
specific comorbidities was taken into account, HRQoL
per se was not a predictor of utilization. According to
Sin and colleagues [20], the presence of comorbidities
was associated with higher scores (implying worse
HRQoL) on St George’s Respiratory Questionnaire
(SGRQ). Similar trends were found in another recent
study of our group [13,14]. Thus, it is most likely that
HRQoL reflected the comorbidity burden.
Limitations
There are a number of limitations in the present study.
First, our database lacked information about reasons
leading to hospitalizations (discharge diagnoses). Second,
estimates of health care utilization may not be applic-
able to other health care systems, as practice patterns
and costs may differ. Third, sleep studies were not part
of our study protocol and the presence of OSA was
assessed using the patients’ medical records. Finally,
over-fitting of our multivariate regression analysis is a
potential concern. We have attempted to be parsimo-
nious regarding the number of explanatory variables,
and have tried to include those that appeared to be bio-
logically and clinically relevant for COPD patients.
These included age, degree of airflow obstruction, body
mass, and overall and specific comorbidity burden.
Further study is needed to substantiate our results.
Conclusions
Compared to controls, COPD patients consume 3.4 times
higher healthcare resources. The “most costly” patients
Table 6 Comparison of the annualized medication cost ($US/person) between the “Most costly” COPD patients and
the remainder
Pharmacological classification “Most costly”* (n = 98) The remainder (n = 291) P value
†
Total 709 (420 - 1171) 340 (191 - 636)
R- Respiratory System 242 (118 - 400) 154 (56 - 330) 0.01
C- Cardiovascular System 78 (24 - 151) 15 (1 - 61) <0.001
A- Alimentary Tract & Metabolism 48 (18 - 103) 9 (2 - 35) <0.001
J- General Antiinfectives for Systemic Use 17 (12 - 31) 12 (6 - 17) <0.001
B- Blood and Blood Forming Organs 14 (3 - 42) 1 (0 - 5) <0.001
N- Nervous System 11 (3 - 40) 4 (1 - 16) <0.001
N02- Analgesics 3.5 (1.5 - 8.5) 1.3 ( 0.3 - 3.5) <0.001
N05, N06- Psycholeptics, Psychoanaleptics 0.8 (0 - 8.6) 0.2 (0 - 3.7) 0.02
M- Musculo-Skeletal System 5 (2 - 25) 4 (1 - 12) 0.01
H- Systemic Hormonal Preparations, Excluding Sex Hormones 4 (1 - 11) 1 (0 - 4) <0.001
D- Dermatologicals 4 (1 - 10) 2 (0 - 7) 0.002
G- Genitourinary System & Sex Hormones 3 (0 - 69) 1 (0 - 17) 0.05
S- Sensory Organs 3 (1 - 11) 1 (0 - 5) <0.001
L- Antineoplastic and Immunomodulating Agents 0 (0 - 0) 0 (0 - 0) 0.001
P- Antiparasitic Products, Insecticides and Repellants 0 (0 - 0) 0 (0 - 0) <0.001
Values are presented as median (25 - 75 percentiles).
* The “most costly” patients are those whose annualized utilization cost was within the upper 25 percentile.
† Mann-Whitney U test.
Table 7 Determinants of the upper quarter most costly
COPD patients
Bivariate analysis
(n = 389)
Multivariate analysis*
(n = 388)
OR 95% CI P
value
OR 95% CI P
value
Age (year +1) 1.03 1.0 - 1.1 0.001 NI
FEV1% 0.99 0.97 - 1.0 0.07 0.99 0.97 - 1.01 0.25
BMI (+1 Kg/m
2) 1.01 1.0 - 1.1 0.50 0.98 0.93 - 1.04 0.54
Age adjusted CCI 1.27 1.2 - 1.4 <0.001 1.09 1.01 - 1.19 0.04
Myocardial infarct 5.96 3.6 - 9.9 <0.001 2.87 1.5 - 5.5 0.001
Congestive heart
failure
6.81 4.1 - 11.4 <0.001 3.52 1.9 - 6.4 <0.001
Mild liver disease 3.14 1.1 - 8.6 0.03 3.83 1.3 - 11.2 0.02
Diabetes mellitus 3.10 1.9 - 5.0 <0.001 2.02 1.1 - 3.6 0.02
Abbreviations: FEV1- forced expired volume in one second (as percent
predicted), BMI- body mass index, CCI- Charlson Comorbidity Index, NI- not
included (due to insignificance).
* Area under ROC curve equals 0.82.
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Page 7 of 8with COPD consumed 63% of all costs and their median
annualized cost was 4.7 times higher compared to the
remainder. Comorbidity burden, not the severity of air-
flow obstruction and HRQoL indices, is the most impor-
tant independent predictor of increased healthcare cost.
Care management of costly patients with COPD should
be the focus of health care decision makers, whose aim is
to efficiently allocate scarce resources. Further study is
needed to evaluate the cost effectiveness of interventions
directed at “costly” COPD patient with specific comor-
bidities to improve their health outcomes.
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